SANA vs. VCEL, CPRX, MLTX, MRUS, BEAM, IBRX, ARWR, HCM, EWTX, and MIRM
Should you be buying Sana Biotechnology stock or one of its competitors? The main competitors of Sana Biotechnology include Vericel (VCEL), Catalyst Pharmaceuticals (CPRX), MoonLake Immunotherapeutics (MLTX), Merus (MRUS), Beam Therapeutics (BEAM), ImmunityBio (IBRX), Arrowhead Pharmaceuticals (ARWR), HUTCHMED (HCM), Edgewise Therapeutics (EWTX), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry.
Sana Biotechnology vs.
Vericel (NASDAQ:VCEL) and Sana Biotechnology (NASDAQ:SANA) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.
Vericel has a net margin of 1.56% compared to Sana Biotechnology's net margin of 0.00%. Vericel's return on equity of 1.48% beat Sana Biotechnology's return on equity.
88.2% of Sana Biotechnology shares are owned by institutional investors. 5.2% of Vericel shares are owned by insiders. Comparatively, 31.1% of Sana Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Vericel has a beta of 1.72, indicating that its stock price is 72% more volatile than the S&P 500. Comparatively, Sana Biotechnology has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500.
Vericel has higher revenue and earnings than Sana Biotechnology. Sana Biotechnology is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.
In the previous week, Vericel had 7 more articles in the media than Sana Biotechnology. MarketBeat recorded 8 mentions for Vericel and 1 mentions for Sana Biotechnology. Vericel's average media sentiment score of 1.40 beat Sana Biotechnology's score of 0.67 indicating that Vericel is being referred to more favorably in the media.
Vericel received 332 more outperform votes than Sana Biotechnology when rated by MarketBeat users. Likewise, 61.86% of users gave Vericel an outperform vote while only 60.61% of users gave Sana Biotechnology an outperform vote.
Vericel presently has a consensus price target of $63.14, indicating a potential upside of 21.43%. Sana Biotechnology has a consensus price target of $14.25, indicating a potential upside of 373.42%. Given Sana Biotechnology's higher possible upside, analysts plainly believe Sana Biotechnology is more favorable than Vericel.
Summary
Vericel beats Sana Biotechnology on 14 of the 17 factors compared between the two stocks.
Get Sana Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for SANA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sana Biotechnology Competitors List
Related Companies and Tools
This page (NASDAQ:SANA) was last updated on 2/21/2025 by MarketBeat.com Staff
